This article reviews the diagnosis and management of the most common respiratory conditions complicating pregnancy-asthma and influenza. We also review strategies for smoking cessation in pregnancy as, in addition to exacerbating all other pulmonary conditions, smoking is the most modifiable risk factor for poor pregnancy outcome. Moreover, the obstetrician frequently encounters each of these conditions in the ambulatory setting. A thorough knowledge of the normal pregnancy-induced physiological respiratory changes combined with a comprehensive understanding of how to manage these conditions, will provide the obstetrician with the armamentarium needed to optimize health outcomes for mothers and their fetuses.
Introduction
The diagnosis and treatment of various respiratory conditions in pregnancy can be challenging. Despite the frequency of these conditions, pregnant women may be improperly diagnosed because of failure to perform diagnostic testing or inadequately treated due to fear of medication teratogenicity. Furthermore, the pregnancy-related physiological changes of the respiratory system, designed to optimize oxygen delivery to the fetus, result in increased maternal susceptibility to respiratory insults, and may complicate the diagnostic evaluation. This article reviews the diagnosis and management of the most common conditions affecting the respiratory system in pregnancyasthma and influenza. A knowledgeable obstetrician can almost always manage these conditions, and proper treatment improves outcomes. We also discuss smoking in pregnancy as the most modifiable risk factor for poor birth outcome. 1 Pregnancy induces profound changes in maternal physiology. Important immunologic changes also occur in pregnancy, in particular, decreased cell-mediated immunity potentiates the risk for infection, rendering pregnant women more susceptible to certain respiratory pathogens.
Asthma in Pregnancy
Asthma is a chronic disease of airway hyperresponsiveness and inflammation with subsequent airflow limitation. It is the most common, potentially serious, respiratory problem complicating pregnancy. In the United States, 3.7% to 8.4% of all pregnant women are asthmatic 2 and the prevalence is increasing. 3 In general, asthma in pregnancy follows the rule of thirds: one third of patients will have improvement of symptoms, one third will worsen, and one third will remain the same. 4 The difficulty in managing asthma in pregnancy is that its course is unpredictable. Although most women with asthma have good pregnancy outcomes, some may experience life-threatening exacerbations requiring hospitalization. For multiparous women, asthma is expected to follow a course similar to previous pregnancies. Because of the high prevalence and unpredictable nature of asthma, the obstetrician should be familiar with its classification, evaluation, and management in pregnancy (Table 1) .
Asthma can result in numerous adverse pregnancy outcomes. After adjustment for comorbidities, studies have demonstrated increased risks of preeclampsia, preterm birth, low birth weight, 7 diabetes mellitus, 8 intrauterine growth restriction, 8 congenital malformations, 9 and higher rates of cesarean delivery in pregnant asthmatics. 10 These risks appear to be higher in women with poorly controlled asthma. 7, 10 Some studies have shown associations between maternal use of oral corticosteroids in the first trimester and subsequent facial clefting in the fetus. 11,12 However, the potential risks associated with asthma medications are lower than the risks associated with uncontrolled asthma, and it is imperative that women continue to use their asthma medications in pregnancy.
DIAGNOSIS
The majority of asthmatics enter pregnancy with a known diagnosis of asthma. However, diagnostic testing is warranted in patients who develop respiratory symptoms for the first time in pregnancy in the absence of a known history. The most common cause of shortness of breath in pregnancy is physiological dyspnea; however, unlike asthma exacerbations, dyspnea of pregnancy is never associated with coughing, wheezing, or chest tightness. Other potential causes of these clinical findings in pregnant women include gasteroesophageal reflux, allergic rhinitis with postnasal drip, bronchitis, pneumonia, pulmonary edema, and pulmonary embolism. In general, the diagnostic evaluation for asthma is similar for pregnant and nonpregnant women. Spirometry is the foundation of the evaluation as it reliably demonstrates airflow obstruction. 13 The diagnosis of asthma is confirmed by a reduced forced expiratory volume in 1 second (FEV 1 ) with Z12% improvement after inhalation of a short-acting bronchodilator as measured by spirometry, or by an increase of Z10% of predicted FEV 1 after inhalation of a short-acting bronchodilator. 13 Peak flow meters are designed for monitoring asthma control and should never be used as diagnostic tools in the office because of significant variability in their reference values for predicted peak expiratory flow measurements. In patients with normal pulmonary function, methacholine testing is often performed to confirm bronchial hyperreactivity. However, methacholine testing is not recommended in pregnancy due to lack of available safety data. 6 If reversibility of airway obstruction cannot be demonstrated after b-agonist administration, yet the clinical picture is consistent with asthma, the patient should be empirically treated for presumed asthma until methacholine testing can be performed postpartum. 6 Most patients with asthma are sensitive to allergens, and up to 85% of the asthmatics will have a positive skin test for Z1 allergens. Skin testing for allergens is recommended for most nonpregnant patients with persistent asthma to help identify potential triggers 13 ; however, it is not recommended in pregnancy as it is associated with systemic reactions and anaphylaxis. As an alternative, pregnant patients with persistent asthma may undergo blood testing for immunoglobulin E antibodies to specific allergens. 6 
CLASSIFICATION OF ASTHMA SEVERITY AND ASTHMA MANAGEMENT
Classification of asthma severity aids asthma management including initiation and adjustment of medication (Table 1 ). Asthma should be classified based on selfreported asthma symptoms during a 2-to 4-week period ( Table 1 ). It is important to recognize that the asthma classification system is dynamic and women may change classes throughout pregnancy. In addition to a complete physical examination, an extensive history should be elicited at the first prenatal visit including number of acute asthma exacerbations, past hospitalizations, history of intubation and mechanical ventilation, prior oral steroid use, and known environmental asthma triggers.
Medical management utilizes a stepwise approach to minimize the amount 800
Orzechowski and Miller www.clinicalobgyn.com of medication used. An important element of management is elimination of triggers such as tobacco smoke, animal dander, pollens, molds, food additives, exercise, cold weather, and some medications (eg, aspirin). Limiting or eliminating exposure to environmental triggers and allergens can reduce symptoms and the need for medical therapy. Some specific measures for allergen control include using mattress and pillow covers, removing pets from the home, removing carpeting, and reducing humidity to prevent mold. If exposure to allergens cannot be successfully eliminated, medications such as antihistamines and leukotriene receptor antagonists may be useful ( Table 2) . Similarly, if exercise is a trigger, inhalation of albuterol 5 to 60 minutes before exercise may prevent exacerbations.
Stepwise guidelines for medical management of asthma are shown in Table 1 and controller medications are shown in Table 2 . Inhaled corticosteroids are the foundation for medical treatment in women with persistent asthma. Women must be counseled on the importance of using their controller medications in pregnancy. A knowledgeable obstetrician can properly manage most pregnant patients with asthma; however, patients with worsening moderate asthma and those with severe asthma should be referred to a maternal-fetal medicine specialist or pulmonologist for additional management.
MONITORING OF ASTHMA IN PREGNANCY
Both the FEV 1 and the peak expiratory flow rate (PEFR) are reliable objective measures of airway obstruction. They are unchanged during pregnancy, and thus ideal for monitoring asthma severity. As FEV 1 can only be measured by spirometry, a handheld peak flow meter for measurement of PEFR is preferred for monitoring asthma control. The average PEFR in pregnancy is 380 to 550 L/min. A baseline ''personal best value'' should be acquired at the first prenatal visit, or preferably at a preconception visit; this value then serves as the reference from which to diagnose an exacerbation or the need for change in the medication regimen. The goal of asthma management is to maintain PEFR measurements at >80% of personal best. 14 Women should be counseled to seek outpatient medical care as soon as possible when PEFR values are within the 50% to 80% range and to seek immediate emergency medical care when the PEFR is <50%. 14 It is helpful to then mark the patient's personal peak flow meter to identify 80%, 50%, and >50% of her personal best.
There is limited data regarding the optimal obstetric care of patients with asthma. Women with poorly controlled asthma are at increased risk of pregnancy complications. 7, 15 Thus, a common regimen includes monthly ultrasounds for growth, and antepartum testing, beginning at 32 weeks.
Pregnant asthmatics should continue their medication regimen as prescribed throughout labor and delivery. If systemic corticosteroids have been used in the previous 4 weeks, stress dose corticosteroids are recommended (hydrocortisone 100 mg every 8 to 12 h during labor and for 24 h postpartum). 6, 14 Regional anesthesia can reduce oxygen consumption in labor and may be used safely in asthmatics. 14 Misoprostol can be used in pregnant asthmatics without significant risk of adverse reactions, but respiratory status should be monitored for bronchospasm. 4, 14 There are no reports of bronchospasm associated with calcium channel blockers. Magnesium sulfate has bronchodilator effects and can be used safely. The use of carboprost, ergonovine, and methylergonovine should be avoided as they have all been associated with bronchospasm. Similarly, indomethacin has been associated with bronchospasm in patients with aspirin sensitivity and should be avoided. 6, 14, 15 Respiratory Issues in Ambulatory Obstetrics 801 
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Patient education is essential for improving compliance and self-monitoring. A significant proportion of acute asthmatic exacerbations in pregnancy have been associated with nonadherence to treatment with inhaled corticosteroids. Below is a checklist to be used by the obstetrician to help ensure that the patients are properly educated.
PATIENT EDUCATION CHECKLIST FOR THE OBSTETRICIAN
Did you counsel the patient on the unpredictable course of asthma in pregnancy? Did you counsel the patient to remain on asthma medications during pregnancy because one third of patients have worsening of their asthma? Did you obtain and record a baseline PEFR measurement at the first prenatal visit? Did you observe and instruct the patient on how to properly obtain PEFR measurements? Did you observe and instruct the patient on proper use of their inhalers? Did you explain how to recognize a severe asthma exacerbation and when to seek medical attention? If the patient smokes, did you strongly encourage smoking cessation? Did you refer her to a smoking cessation program and offer nicotine replacement therapy (NRT) if indicated? Did you identify potential triggers for asthma? Common triggers include animal dander, cockroach antigens, pollens, molds, tobacco smoke, food additives, exercise, and some medications such as aspirin and b-blockers.
Have you counseled the patient on how to avoid or limit exposure to allergens?
Influenza in Pregnancy
In the United States, influenza is the eighth leading cause of death, 16 resulting in over 36,000 deaths and 200,000 hospitalizations annually. During the influenza season (October to April), 5% to 20% of the general population will become infected with the virus. 17 Influenza viruses that infect humans are classified into 3 principal types: A, B, and C. Types A and B are associated with seasonal epidemics. Type A can cause pandemics. Minor mutations in the surface proteins of influenza A viruses (antigenic drift) occur continuously altering the virus enough so that influenza vaccines must be updated annually. Significant changes in the surface proteins of influenza A viruses occur through mutation of avian or swine viruses resulting in the development of new human subtypes (antigenic shift); these novel influenza strains are responsible for influenza pandemics and typically result in high rates of morbidity and mortality due to the lack of immunity in the population.
The direct effects of influenza infection on the fetus are unknown. In seasonal influenza epidemics, viremia is thought to occur infrequently and vertical transmission is rare, 18 although this may differ with new influenza strains. 19 Although there is no evidence that influenza viruses are teratogenic, adverse pregnancy outcomes such as spontaneous abortion, stillbirth, and preterm birth have been reported after both pandemic and seasonal influenza. 20 In addition, animal and human studies suggest that significant fever may be associated with an increased risk for birth defects. 21, 22 Pregnancy is a risk factor for increased maternal morbidity and mortality from both pandemic and seasonal influenza. Unlike seasonal influenza, pandemic influenza infections typically affect younger patients. Pregnant women with influenza infection have significantly higher rates of hospitalization compared with their nonpregnant counterparts, and are more likely to be admitted to an intensive care unit due to severe respiratory compromise. [23] [24] [25] The Center for Disease Control (CDC)
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reported that out of 347 severely ill pregnant women with H1N1 influenza infection in 2009, there were 75 deaths and 272 admissions to intensive care units. 26 Many of these severely ill women were in the third trimester of pregnancy as disease severity increases with advancing gestational age. 23, 27, 28 Not surprisingly, women with underlying medical conditions are also at risk for more severe infection. During the 2009 H1N1 pandemic, asthma was the most common comorbid condition among women with severe influenza infection. [23] [24] [25] [26] [27] [28] [29] 
DIAGNOSIS AND TESTING FOR INFLUENZA
The influenza virus is spread through aerosolized respiratory droplets with symptoms typically developing 1 to 4 days after exposure. Seasonal influenza infection causes fever, chills, dry cough, headache, malaise, nausea, vomiting, rhinorrhea, and myalgia. In the 2009 H1N1 pandemic, symptoms were similar to seasonal influenza infection, but gastrointestinal symptoms such as diarrhea and vomiting were more frequent. 28 Recommendations for laboratory tests differ between seasonal and pandemic strains. Several effective laboratory tests exist including direct antigen detection tests, viral cell culture of nasopharyngeal or throat samples, and detection of influenza-specific RNA by real-time reverse transcriptasepolymerase chain reaction. Because of the historically poor sensitivity of rapid influenza tests (ranging from 10% to 80%), clinical decisions about treatment should not be guided or delayed by negative rapid test results. 30 If influenza is prevalent in the community, women with uncomplicated illness can be diagnosed clinically, and influenza testing is not needed for antiviral treatment. Clinicians should use clinical judgment to decide when to test for influenza in women who are not severely ill as diagnostic testing may help inform decisions regarding infection control or management of close contacts. If testing for pandemic influenza is warranted, the CDC recommends the Human Influenza Virus Real-Time RT-PCR influenza panel assay for confirmation. 30 
MANAGEMENT OF INFLUENZA
Antiviral medications play an important role both for the postexposure prophylaxis and for treatment of infected pregnant women, particularly during pandemics. The use of antiviral medications can significantly reduce maternal morbidity and mortality from influenza. Infected women who receive early antiretroviral treatment have lower rates of intensive care unit admission and death. 22, 23 Therefore, antiviral treatment is recommended as soon as possible for any women with confirmed or suspected influenza regardless of gestational age. 31 Antiviral medications are most effective when started within 48 hours of the onset of symptoms, but may still have some benefit in pregnant women when administered beyond 48 hours. 23 Treatment should never be delayed while awaiting diagnostic tests results. 31 Pregnant women may be offered antiviral prophylaxis within 48 hours after exposure to a person with confirmed, probable, or suspected influenza infection; however, if availability of medication is an issue, public health authorities may recommend that antivirals be prescribed only for treatment. 32 For the 2011 to 2012 influenza season, 2 Food and Drug Administration-approved neuraminidase inhibitors, zanamivir (Relenza) and oseltamivir (Tamiflu), are available for postexposure prophylaxis and treatment. 32 Two older anti-influenza medications, rimantidine and amantadine, are not recommended because of high rates of resistance among circulating influenza A viruses. 31 Oseltamivir is preferred for both treatment and chemoprophylaxis in pregnant women as more safety data are available. To date, no teratogenic effects have been identified with either of these 2 medications and, considering the severity of
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Orzechowski and Miller disease, treatment benefits appear to outweigh any potential risks. 33, 34 Pregnant women being treated for confirmed or suspected influenza infection should be counseled on when to seek emergency medical care. Obstetricians should have a very low threshold for hospital admission in patients presenting with difficulty breathing or shortness of breath, pain or pressure in the chest, contractions and/ or symptoms of labor, sudden dizziness, confusion, persistent vomiting, decreased or no fetal movement (in the third trimester), or a fever that is not responding to antipyretic therapy. Pregnant women with influenza should be treated aggressively with antipyretic therapy, and should adhere to standard recommendations for folic acid consumption. 35 
PREVENTION
Pregnant and postpartum women represent a vulnerable population; influenza vaccination should be an integral element of prenatal care. Historically, influenza vaccination rates in pregnancy have been unacceptably low; the highest vaccination rate was achieved in the 2009 to 2010 influenza season where 32% of pregnant women were vaccinated. 36 The Advisory Committee on Immunization Practices (ACIP), the Center for Disease Control (CDC), and the American College of Obstetricians and Gynecologists (ACOG) recommend annual inactivated influenza vaccination for women who will be pregnant during the influenza season. Inactivated influenza vaccination may be given in all the 3 trimesters of pregnancy. 37 Women with underlying respiratory and medical conditions are at even greater risk for complications.
Multidose vials of the vaccine contain trace thimerisol, a mercury-containing preservative, which has not been linked to neonatal or childhood adverse outcomes. The ACIP and CDC recommend vaccination regardless of thimerosal content. Thimerosal-free vaccines are available in single-dose vials and may be used depending on patient preference. No study to date has shown any adverse consequences of influenza vaccination in pregnant women. 38 Preliminary results from a trial of the 2009 H1N1 nonadjuvanted vaccine showed an immune response in pregnant women similar to the response in nonpregnant adults. No safety concerns were identified. 39 The live, attenuated influenza virus vaccine, available as an intranasal spray, is not approved for use during pregnancy given the theoretical risk associated with use of a live vaccine.
Immunity in the mother and close household contacts is the only effective strategy to prevent influenza infection in the newborn as the vaccine is not approved for use in infants less than 6 months of age. Multiple studies have demonstrated fewer cases of laboratory-confirmed influenza and lower rates of respiratory infections with fever among infants born to immunized mothers compared with infants of unimmunized women. [40] [41] [42] Immunized mothers who breastfeed provide their infants with maternal antibodies to influenza thereby conferring additional protection. Conversely, bottle-fed infants are more vulnerable to influenza and other respiratory infections, and are at increased risk for hospitalization. The risk of influenza transmission through breast milk is unknown; reports of viremia with seasonal influenza are rare that suggests that transmission of influenza into breast milk is also rare. Women who are ill with influenza should continue to breastfeed. To prevent respiratory transmission to breastfed infants, it is recommended that women with influenza-like illness use facemasks and proper hand hygiene when providing infant care and feedings. Women who are acutely ill may pump their milk for bottle feedings by a healthy family member.
Smoking in Pregnancy
Approximately 13% of pregnant women in the United States smoke, 43 
making it
Respiratory Issues in Ambulatory Obstetrics 805 one of the most preventable causes of both maternal and fetal morbidity and mortality. In addition to the known maternal health consequences, smoking is also associated with numerous adverse pregnancy and perinatal outcomes related to impaired placental gas exchange, placental insufficiency, and direct toxic effects to the fetus. These adverse outcomes include placenta previa, placental abruption, preterm premature rupture of membranes, preterm birth, intrauterine growth restriction, stillbirth, low birth weight, and sudden infant death syndrome. Direct toxic effects to the fetus include possible facial clefting 44, 45 and decreased intelligence. 46 Smoking also impairs fertility, and increases the risk of ectopic pregnancy and spontaneous abortion. 47
PREGNANCY: A UNIQUE OPPORTUNITY FOR SMOKING CESSATION
Most women seek medical care at some point during pregnancy providing the physician with a unique opportunity for smoking cessation intervention. Women are more likely to quit smoking during pregnancy than at any other time in life making pregnancy a ''teachable moment,'' 48, 49 yet less than a third of obstetricians refer patients to smoking intervention programs. 50 Approximately 20% of smokers will successfully abstain during pregnancy. 51 Women who smoke r10 cigarettes/d before pregnancy have quit rates double those women who smoke >10 cigarettes/d. 52 Women who successfully quit smoking in pregnancy are at very high risk of relapse in the postpartum period with relapse rates as high as 60% in the first 6 months, therefore it is essential that interventions continue into the postpartum period. 50 Smoking cessation in pregnancy can decrease the risk of an adverse pregnancy outcome. Women who receive smoking cessation interventions have a reduction in low birth weight infants and preterm birth, indicating that smoking cessation in pregnancy may slow or reverse its adverse effects on perinatal outcomes. 53 There is evidence to suggest that women who quit smoking as late at 32 weeks of gestation deliver infants with higher birth weights compared with those who continue to smoke. 54 
SMOKING CESSATION STRATEGIES
Smoking is a complex and variable behavior that has many social, behavioral, and physiological triggers. Smoking cessation interventions include cognitive behavioral therapy (eg, coping skills training or behavioral contracting), interventions based on stages of change (eg, consciousness raising techniques for patients in precontemplation stage), providing feedback on fetal health status or nicotine by-product measurements, and/or pharmacological treatment. 1 In a large meta-analysis, trials using cognitive behavioral therapy and incentives as the main intervention strategy demonstrated statistically significant improvements in infant birth weight. 1 There is a general consensus among experts that behavioral interventions should be encouraged before pharmacological approaches are used. Women should be asked about tobacco use and offered effective smoking cessation interventions at the first prenatal visit and again at each prenatal visit including postpartum follow-up visits. Pregnant smokers should receive augmented intervention through counseling by the obstetrician, pregnancy-specific self-help materials, and counseling sessions with a health educator. 55 Brief smoking cessation counseling in conjunction with administration of pregnancy-specific self-help materials can significantly improve cessation rates compared with cessation rates achieved with just advice to quit. 56 ACOG endorses the 5As method of smoking cessation intervention adapted for use during pregnancy. 49, 55, 57 The 5 As of Smoking Cessation
1.
Ask the patient about tobacco use. 2. Advise her to quit. 3. Assess her willingness to make a quit attempt. 4. Assist in her quit attempt. 5. Arrange follow-up. Counseling alone may not significantly increase cessation rates particularly in moderate to heavy smokers as it does not address the issue of physiological dependence. 58 Many smokers will experience symptoms of nicotine withdrawal, which can have a substantial negative influence on attempts at smoking cessation. 59 Nicotine replacement products can help ease the symptoms of nicotine withdrawal. However, the data regarding the safety of nicotine replacement products in pregnancy are conflicting and more information is needed about their risks in pregnancy before evidence-based recommendations can be made. 1, 60, 61 Of the possible pharmacological interventions, NRT is the treatment of choice in pregnancy in women who are moderate to heavy smokers or who are highly dependent and have been unable to quit. 61, 62 The goal of NRT is to provide a level of nicotine just above that associated with withdrawal symptoms. The risk/benefit ratio for the use of pharmacotherapy for smoking cessation in pregnancy appears favorable in those who smoke >10 cigarettes/d (moderate to heavy smokers). Two randomized control trials have found that women using nicotine gum 63 or the nicotine patch 64 had infants with significantly higher birth weights compared with smokers receiving placebo.
In evaluating the risk/benefit ratio of NRT, clinicians may focus not only on the risks to the fetus, but also on maternal health benefits and the long-term health risks for infants that extend into adulthood. Transdermal nicotine patches are recommended to help with smoking cessation efforts in heavy smokers who have failed nonpharmacologic interventions. 49 Because the total amount of nicotine exposure to the fetus is less with NRT than with moderate to heavy smoking. Also, the developing fetus is not exposed to the other toxic substances found in cigarettes.
